BR0316895A - Composto, processo para a preparação do composto, composição farmacêutica, novos intermediários, processo para a preparação dos novos intermediários e uso do composto - Google Patents

Composto, processo para a preparação do composto, composição farmacêutica, novos intermediários, processo para a preparação dos novos intermediários e uso do composto

Info

Publication number
BR0316895A
BR0316895A BR0316895-6A BR0316895A BR0316895A BR 0316895 A BR0316895 A BR 0316895A BR 0316895 A BR0316895 A BR 0316895A BR 0316895 A BR0316895 A BR 0316895A
Authority
BR
Brazil
Prior art keywords
compound
preparation
new intermediates
pharmaceutical composition
intermediates
Prior art date
Application number
BR0316895-6A
Other languages
English (en)
Other versions
BRPI0316895B1 (pt
BRPI0316895C1 (pt
BRPI0316895B8 (pt
Inventor
Venkata Satya Niro Ramakrishna
Vikas Shreekrishna Shirsath
Rama Sastri Kambhampati
Venkata Satya Veerabhadra Rao
Venkateswarlu Jasti
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of BR0316895A publication Critical patent/BR0316895A/pt
Publication of BRPI0316895B1 publication Critical patent/BRPI0316895B1/pt
Publication of BRPI0316895B8 publication Critical patent/BRPI0316895B8/pt
Publication of BRPI0316895C1 publication Critical patent/BRPI0316895C1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Optics & Photonics (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)

Abstract

"COMPOSTO, PROCESSO PARA A PREPARAçãO DO FARMACêUTICA, NOVOS INTERMEDIáRIOS, PROCESSO PARA A PREPARAçãO DOS NOVOS INTERMEDIáRIOS E USO DO COMPOSTO". A presente invenção refere-se a novos indolos substituídos de tetracíclicos 3-substituídos, representados pela fórmula geral (I), aos seus estereoisómeros, aos seus radio isótopos, aos seus óxidos de N, aos seus polimorfos, aos seus sais farmaceuticamente aceitáveis, aos seus solvatos farmaceuticamente aceitáveis, aos seus metabólitos bio ativos úteis e a qualquer combinação dos acima mencionados assim como aos processos para a preparação de tais compostos da fórmula geral (I, dos seus estereoisómeros, dos seus radio isótopos, dos seus óxidos de N, dos seus polimorfos, dos seus sais farmaceuticamente aceitáveis, dos seus solvatos farmaceuticamente aceitáveis, dos seus metabólitos bio ativos úteis e também inclui qualquer combinação adequada dos acima mencionados.
BRPI0316895A 2002-12-18 2003-12-16 composto, processo para a preparação do composto, composição farmacêutica e uso do composto BRPI0316895C1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN951MA2002 2002-12-18
IN951/MAS/2002 2002-12-18
PCT/IN2003/000393 WO2004055026A1 (en) 2002-12-18 2003-12-16 Tetracyclic 3-substituted indoles having serotonin receptor affinity

Publications (4)

Publication Number Publication Date
BR0316895A true BR0316895A (pt) 2005-10-25
BRPI0316895B1 BRPI0316895B1 (pt) 2018-07-24
BRPI0316895B8 BRPI0316895B8 (pt) 2019-09-03
BRPI0316895C1 BRPI0316895C1 (pt) 2021-05-25

Family

ID=40848934

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0316895A BRPI0316895C1 (pt) 2002-12-18 2003-12-16 composto, processo para a preparação do composto, composição farmacêutica e uso do composto

Country Status (20)

Country Link
US (1) US7781476B2 (pt)
EP (1) EP1581538B1 (pt)
JP (1) JP4571507B2 (pt)
KR (1) KR100739987B1 (pt)
CN (1) CN100378109C (pt)
AT (1) ATE355292T1 (pt)
AU (1) AU2003292510B2 (pt)
BR (1) BRPI0316895C1 (pt)
CA (1) CA2507923C (pt)
DE (1) DE60312226T2 (pt)
DK (1) DK1581538T3 (pt)
EA (1) EA009367B1 (pt)
HK (1) HK1083840A1 (pt)
MX (1) MXPA05005808A (pt)
NO (1) NO334030B1 (pt)
NZ (1) NZ540841A (pt)
PT (1) PT1581538E (pt)
SI (1) SI1581538T1 (pt)
WO (1) WO2004055026A1 (pt)
ZA (1) ZA200504042B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005005439A1 (en) * 2003-07-09 2005-01-20 Suven Life Sciences Limited Benzothiazino indoles
EA010406B1 (ru) 2004-01-02 2008-08-29 Сувен Лайф Сайенсиз Лимитед Новые индено[2,1-a]индены и изоиндоло[2,1-a]индолы
BRPI0520054B1 (pt) * 2005-03-08 2018-07-10 Suven Life Sciences Limited Processo para a preparação de benzotiazinoindolas substituídas
ES2337167T3 (es) 2005-08-12 2010-04-21 Suven Life Sciences Limited Derivados de sulfonamida aminoarilos como ligandos funcionales 5ht6.
KR101250820B1 (ko) 2005-08-16 2013-04-04 수벤 라이프 사이언시스 리미티드 개선된 로사르탄 제조 방법
CN101553467B (zh) 2007-01-08 2011-12-07 苏文生命科学有限公司 5-(杂环基)烷基-n-(芳基磺酰基)吲哚化合物及其作为5-ht6配体的用途
DK2155674T3 (da) 2007-05-03 2011-09-26 Suven Life Sciences Ltd Aminoalkoxy-aryl-sulfonamidforbindelser og anvendelse heraf som 5-HT6-ligander
US7807705B2 (en) 2007-05-18 2010-10-05 The Ohio State University Research Foundation Potent indole-3-carbinol-derived antitumor agents
JP5236001B2 (ja) 2007-10-26 2013-07-17 スヴェン・ライフ・サイエンシズ・リミテッド アミノアリールスルホンアミド化合物および5−ht6リガンドとしてのその使用
DK2346847T3 (da) 2008-09-17 2013-08-05 Suven Life Sciences Ltd Arylsulfonamidaminforbindelser og deres anvendelse som 5-ht6-ligander
WO2010032257A1 (en) 2008-09-17 2010-03-25 Suven Life Sciences Limited Aryl indolyl sulfonamide compounds and their use as 5-ht6 ligands
US8153680B2 (en) 2009-08-25 2012-04-10 The Ohio State University Research Foundation Alkyl indole-3-carbinol-derived antitumor agents
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
NZ719671A (en) * 2013-12-02 2017-03-31 Suven Life Sciences Ltd Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate
RS58575B1 (sr) * 2014-08-16 2019-05-31 Suven Life Sciences Ltd Aktivni metabolit 1-[(2-bromofenil) sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil) metil]-1h-indol dimezilat monohidrata i dimezilat dihidrat so aktivnog metabolita
AU2018297653C1 (en) * 2017-07-03 2022-03-31 Suven Life Sciences Limited New uses of a pure 5-HT6 receptor antagonist

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3489429A (en) * 1967-12-18 1970-01-13 American Home Prod 1-loweralkanoyl-3-(2-substituted ethyl)indoles
BE889931A (fr) * 1980-08-12 1982-02-11 Glaxo Group Ltd Derives indoliques, leur preparation et leurs applications en tant que medicaments
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8719167D0 (en) 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
GB8724912D0 (en) 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
GB8819024D0 (en) 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds
IL96891A0 (en) 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
CA2042295A1 (fr) 1990-05-15 1991-11-16 Jacques Chauveau Derives de mediateurs endogenes, leurs sels, procede de preparation, applications, et compositions les renfermant
EP0486666B1 (en) 1990-06-07 1997-08-13 Zeneca Limited Therapeutic heterocyclic compounds
SK278998B6 (sk) 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
GB9113802D0 (en) 1991-06-26 1991-08-14 Smithkline Beecham Plc Medicaments
GB9210400D0 (en) 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
KR940007001A (ko) 1992-09-16 1994-04-26 최승주 새로운 n-신나모일-2-메틸-5-메톡시-3-인돌 아세트산 에스테르, 그 제조방법 및 이를 함유하는 약학적 제제
FR2737220B1 (fr) 1995-07-24 1997-09-26 Adir Sequences nucleiques codant pour des recepteurs de la melatonine et leurs applications
JP2000026471A (ja) * 1998-07-10 2000-01-25 Nippon Soda Co Ltd 11−ホルミル−インドロ[1,2−b][1,2]ベンズイソチアゾールおよび農園芸用殺菌剤
GB9820113D0 (en) 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
DK1149078T3 (da) * 1998-12-11 2006-07-10 Univ Virginia Commonwealth Selektive 5-HT6-receptorligander
US6403808B1 (en) * 1999-12-10 2002-06-11 Virginia Commonwealth University Selective 5-HT6 receptor ligands
IL130169A (en) 1999-05-27 2006-08-20 Neurim Pharma 1991 Indole derivatives, and pharmaceutical preparations, skin protection preparations, and cosmetics containing them
FR2799757B1 (fr) * 1999-10-15 2001-12-14 Adir Nouveaux derives polycycliques azaindoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN1317276C (zh) * 2000-09-29 2007-05-23 中国科学院上海药物研究所 一类吲哚基哌啶类化合物及其制备方法和用途
EP1341782A2 (en) 2000-11-20 2003-09-10 Scios Inc. Inhibitors of p38 kinase
FR2821843B1 (fr) * 2001-03-12 2003-05-09 Servier Lab Nouveaux derives d'isoindoloindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20070270432A1 (en) 2002-02-05 2007-11-22 James Hagan Novel Method
CN100378108C (zh) * 2002-06-21 2008-04-02 苏文生命科学有限公司 对血清素受体具有亲和力、可用作治疗剂的新型四环芳基磺酰吲哚、其制备方法及其药物组合物
BR0312175A (pt) * 2002-06-21 2005-04-05 Suven Life Sciences Ltd Composto, composição farmacêutica, uso de um composto, método para o tratamento e método para reduzir a morbidez e a mortalidade associadas com o excesso de peso
PT1567492E (pt) * 2002-11-28 2013-07-22 Suven Life Sciences Ltd N-arilsulfonil-3-aminoalcoxi-indóis

Also Published As

Publication number Publication date
ATE355292T1 (de) 2006-03-15
NZ540841A (en) 2008-08-29
WO2004055026A8 (en) 2005-06-23
KR20050084185A (ko) 2005-08-26
DE60312226D1 (de) 2007-04-12
PT1581538E (pt) 2007-05-31
BRPI0316895B1 (pt) 2018-07-24
EA200500994A1 (ru) 2006-02-24
BRPI0316895C1 (pt) 2021-05-25
JP4571507B2 (ja) 2010-10-27
NO20052909D0 (no) 2005-06-15
EP1581538A1 (en) 2005-10-05
NO334030B1 (no) 2013-11-18
EA009367B1 (ru) 2007-12-28
CN1729197A (zh) 2006-02-01
JP2006515843A (ja) 2006-06-08
AU2003292510B2 (en) 2009-04-23
US7781476B2 (en) 2010-08-24
KR100739987B1 (ko) 2007-07-16
AU2003292510A1 (en) 2004-07-09
BRPI0316895B8 (pt) 2019-09-03
NO20052909L (no) 2005-09-12
US20070142398A1 (en) 2007-06-21
DK1581538T3 (da) 2007-06-25
WO2004055026A1 (en) 2004-07-01
MXPA05005808A (es) 2005-09-08
ZA200504042B (en) 2006-01-26
HK1083840A1 (en) 2006-07-14
CA2507923C (en) 2010-02-02
DE60312226T2 (de) 2007-11-15
EP1581538B1 (en) 2007-02-28
CN100378109C (zh) 2008-04-02
CA2507923A1 (en) 2004-07-01
SI1581538T1 (sl) 2007-08-31

Similar Documents

Publication Publication Date Title
BR0316895A (pt) Composto, processo para a preparação do composto, composição farmacêutica, novos intermediários, processo para a preparação dos novos intermediários e uso do composto
BR0315959A (pt) Composto, composição farmacêutica uso do composto, método para o tratamento, método para reduzir a morbidez e a mortalidade associadas com o excesso de peso e processo para a preparação do composto
BR0112756A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina, de congestão nasal, asma alérgica, e rinite alérgica, e, uso de um composto
UY26511A1 (es) Bases de mannich indólicas, procedimientos para su preparación, medicamentos que contienen estos compuestos y su uso para la preparación de medicamentos
BR0112292A (pt) Composto, composição farmacêutica, método para tratar ou prevenir disfunções tromboembólicas e uso de um composto
EE04915B1 (et) Kinuklidiinderivaadid, nende valmistamismeetod, vahehendid, farmatseutiline kompositsioon ja nende kasutamine
BR0315681A (pt) Composto e seus sais e hidratos farmaceuticamente aceitáveis, composição farmacêutica, métodos para o tratamento de doenças mediadas pela prostaglandina d2, para o tratamento de congestão nasal, para o tratamento de asma alérgica, e para o tratamento de rinite alérgica, composto ou um seu sal ou solvato farmaceuticamente aceitável, sal ou hidrato do composto, e, uso de um composto ou de um seu sal ou solvato farmaceuticamente aceitável
BRPI0407508B8 (pt) compostos derivados de bifenila, composição farmacêutica e uso dos mesmos
BR0209580A (pt) Derivados de ciclohexan-1, 4 diamina substituìdos
TW200635897A (en) Piperidine derivatives and their use as anti-inflammatory agents
EA200100748A1 (ru) Ингибиторы обратного захвата моноаминов для лечения расстройств цнс
ATE340796T1 (de) Dihydropyrrolo(1,2-aöindol- und tetrahydropyrido)1,2-aöindolderivate als prostaglandin rezeptor antagonisten
NO329884B1 (no) Indolderivater, farmasoytisk formulering, anvendelse av forbindelsene, fremgangsmate for fremstilling derav samt mellomprodukter for anvendelse i fremgangsmaten
EA200200291A1 (ru) Производные биариловых эфиров, полезные в качестве ингибиторов обратного захвата моноамина
BRPI0516003A (pt) composto, uso em um composto ou um éster, um sal farmaceuticamente aceitável ou um hidrato do mesmo, formulação farmacêutica, e, método para a triagem in vitro de ligandos de receptor de prostanóide seletivos
BRPI0412695A (pt) derivados de quinolina e quinazolina dotados de afinidade para receptores do tipo 5ht1
NO20061737L (no) Aminosubstituerte erylamino B2 adrenergiske receptoragonister
EA200300183A1 (ru) Новое сочетание агониста (5-th2) и антагониста (5-ht6) серотонина в качестве фармацевтической композиции
BR0008753B1 (pt) Composto de amida, processo para preparar um composto de amida, composição farmacêutica e uso de um composto de amida
DK1212320T3 (da) Phenylpiperazinderivater som inhibitorer for genoptag af serotonin
NO963731L (no) Behandling av obsessive-kompulsive sykdommer med 5HT2-antagonister
ATE308522T1 (de) Opioidrezeptorantagonisten
EE200100328A (et) Antihistamiinsed spiroühendid, vaheühendid ja farmatseutiline kompositsioon ning nende valmistamismeetodid
DK1861360T3 (da) Pyrrolidin-derivater som histamin-H3-receptorantagonister
MXPA04000908A (es) Compuestos farmaceuticamente activos que tienen estructura de anillo de pirazolotriazolopirimidina triciclica y metodos de uso.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/07/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/07/2018, OBSERVADAS AS CONDICOES LEGAIS. (CO) REFERENTE A RPI 2481 DE 24/07/2018, QUANTO AO ITEM (54) TITULO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/12/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2649 DE 13-10-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.